SCHEMBL5504982

SCHEMBL5504982

CC(C)c1ccc2[nH]c(-c3ccc(Cl)c(S(=O)(=O)NC4CCCCC4)c3)c(CC(=O)O)c2c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 6/20 0.47
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
TLR8 Q9NR97 4/20 0.41
TLR7 Q9NYK1 4/20 0.41
PTGDR2 Q9Y5Y4 2/20 0.40
LMNA P02545 2/20 0.38
TP53 P04637 2/20 0.38
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TLR9 Q9NR96 3/20 0.36
PI4KB Q9UBF8 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5508339 0.89 BRD4 (0.48) BRD4KDM4EGAATLR8TLR7
SCHEMBL5511392 0.89 BRD4 (0.50) BRD4KDM4ETLR8TLR7PTGDR2
SCHEMBL5506404 0.88 BRD4 (0.49) BRD4TLR8TLR7PTGDR2LMNA
SCHEMBL5622879 0.87 BRD4 (0.47) BRD4TLR8TLR7PTGDR2LMNA
SCHEMBL5514824 0.87 BRD4 (0.49) BRD4KDM4EGAATLR8TLR7
SCHEMBL2874923 0.87 BRD4 (0.49) BRD4KDM4EGAATLR8TLR7
SCHEMBL5509087 0.87 BRD4 (0.47) BRD4KDM4ETLR8TLR7PTGDR2
SCHEMBL5512629 0.86 BRD4 (0.50) BRD4KDM4EGAAPTGDR2ALDH1A1
SCHEMBL5506423 0.84 BRD4 (0.48) BRD4GAAPTGDR2LMNATP53
SCHEMBL5504979 0.83 BRD4 (0.45) BRD4TLR8TLR7PTGDR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265278-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2007-11-15 US claimed
EP-1844011-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS Aventis Pharmaceuticals Inc. (US) 2007-10-17 EP claimed
WO-2006081343-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2006-08-03 WO claimed
US-20070265278-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2007-11-15 US disclosed
US-20070265278-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2007-11-15 US disclosed
US-20070265278-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2007-11-15 US disclosed
EP-1844011-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS Aventis Pharmaceuticals Inc. (US) 2007-10-17 EP disclosed
WO-2006081343-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265278-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS PTGDR2, PTGDR, CYSLTR2 BRD4 2086/4885KDM4E 4109/4885GAA 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.